Market research
ZSAN Zosano Pharma Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- 0.0%
- Beta
- 3.29
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US98979H3012
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- 0.0%
- Beta
- 3.29
About
About Zosano Pharma Corp
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ZSAN discussion.
5 years, 4 months ago
Zosano Pharma Corporation is currently in a long term downtrend where the price is trading 6.4% below its 200 day moving average.
From a valuation standpoint, the stock is 71.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 375.9.
Zosano Pharma Corporation's total revenue rose by inf% to $224K since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow grew by 14.8% to $-7M since the same quarter in the previous year.
Based on the above factors, Zosano Pharma Corporation gets an overall score of 4/5.